H-2 Antigens pp 589-610 | Cite as

MHC Antigen Expression in Malignant Tumours and Their Effects on Host-Tumour Interaction

  • Hilliard Festenstein
  • Mario Labeta
Part of the NATO ASI Series book series (NSSA, volume 144)

Abstract

The development of malignant tumours and their immune regulation depends on a variety of factors including the presence or absence of tumour cell associated antigens (TAA) and the quantitative and qualitative representation of major histocompatibility complex (MHC) determinants in the tumour cells. Investigations of the latter and their importance in relation to host tumour interaction has been the main thrust of our research in this area over the last ten years. Increased or decreased expression of syngeneic Class I and Class II molecules as well as the expression of aberrant “allospecificities” may in different ways affect the immunosurveillance of tumours, their growth rate, as well as their metastatic potential. Our original experimental findings included the observations that certain tumour cells (a) selectively fail or express very weakly the specificities of one of the syngeneic H-2 Class I loci and/or (b) express novel H-2 “allospecificities” as determined by antibody testing.

Keywords

Major Histocompatibility Complex Gene Major Histocompatibility Complex Antigen Neuraminidase Treatment Syngeneic Tumour Major Histocompatibility Complex Antigen Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bishop, C.E., Lewis, C.M. & Festenstein, H.: Dominant allele-specific regulation of expression of H-2Kk gene products revealed by somatic cell hybridisation. Somatic Cell Genetics, 8: 623–634, 1982.PubMedCrossRefGoogle Scholar
  2. Bonavida, B.: The SLJ/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumour interactions, and the regulation of tumour growth. Adv. Cancer Res., 38: 1–22, 1983.PubMedGoogle Scholar
  3. Brickell, P., Latchman, D., Murphy D., Willison, K. & Rigby, P.W.J.: The Class I major histocompatibility antigen gene activated in a line of SV-40-transformed mouse cells is H-2Dd, not Qa/Tla. Nature 316: 162–163, 1985.PubMedCrossRefGoogle Scholar
  4. Festenstein, H., Garrido, F., Matossian-Rogers, A., Schirrmacher, V., Schmidt, W., DeGiorgi, L., Biasi, G. & Jaraquemada, D.: The major histocompatibility system, tumours and viruses, in: HLA System, New Aspects (ed. G.B. Ferrara ), Elsevier/North Holland Biomedical Press, p. 53–67, 1977.Google Scholar
  5. Festenstein, H. & Schmidt, W.: Variation in MHC antigenic profiles of tumour cells and its biological effects. Immunological Rev., 60: 85–127, 1981.CrossRefGoogle Scholar
  6. Festenstein, H., Alonzo, A., Ferluga, J., Ma, B.L., Santamaria, O., Marelli, O., Schmidt, W. & Flavell, R.A.: Further molecular and functional evidence for the expression of H-2 allodeterminants on the AKR leukaemia, K36. Transpl. Proc., 15: 2107–2110, 1983.Google Scholar
  7. Festenstein, H. & Hui, K.M.: Aberrant H-2-like allospecificities on K36.16 thymoma. Studies of radiobinding and immunoprecipitation with anti-H-2 monoclonal antibodies. J. Immunogenetics, 13: 113–116, 1986.CrossRefGoogle Scholar
  8. Garrido, F., Festenstein, H. & Schirrmacher, V.: Further evidence for derepression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature, 261: 705–707, 1976a.PubMedCrossRefGoogle Scholar
  9. Garrido, F., Schirrmacher, V. & Festenstein, H.: H-2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection. Nature, 259: 228–230, 1976b.PubMedCrossRefGoogle Scholar
  10. Garrido, F., Schirrmacher, V. & Festenstein, H.: Studies on H-2 specificities on mouse tumour cells by a new microradioassay. J. Immunogenetics, 4: 15–27.Google Scholar
  11. Garrido, F., Schmidt, W. & Festenstein, H.: Immunogenetic studies on Meth.A vaccinia tumour cells in vivo and in vitro. J. Immunogenetics, 4: 115–125, 1977.CrossRefGoogle Scholar
  12. Hammerling, G.J., Klar, D., Katzav, S., Segal, S., Feldman, M., Wallich, R. & Hammerling, A.: Manipulation of metastasis and tumour growth by transfection with histocompatibility Class I genes. J. Immunogenetics, 13: 153–157, 1986.CrossRefGoogle Scholar
  13. Hui, K.M., Grosveld, F. & Festenstein, H.: Rejection of transplantable AKR leukaemia following MHC DNA-mediated cell transformation. Nature, 311: 750–752, 1984.PubMedCrossRefGoogle Scholar
  14. Hui, K.M., Matossian-Rogers, A., Festenstein, H. & Grosveld, F.: Demonstration of cytostasis and H-2Kk antigen expression in an H-2Kk-deficient AKR leukaemia following DNA-mediated gene transfer. Transpl. Proc., 17: 955–956, 1985.Google Scholar
  15. Hui, K.M., Minamide, L., Prandoni, N., Festenstein, H. & Grosveld, F.G.: Structural variations in thè H-2 genes of AKR lymphomas. J. Immunogenetics, 13: 117–121, 1986.CrossRefGoogle Scholar
  16. Invernizzi, G. & Parmiani, G.: Tumour associated transplantation antigens of chemically induced sarcoma cross-reacting with allogeneic histocompatibility antigens. Nature, 254: 713, 1975.PubMedCrossRefGoogle Scholar
  17. Katzav, S., Tartokovsky, B., de Baetselier, P., Isakov, N., Feldman, M. & Segal, S.: H-2 and other major histocompatibility complexes; Biologic function. Transpl. Proc., 15: 162–170, 1983.Google Scholar
  18. Labeta, M.O., Fernandez, N. & Festenstein, H.: Solubilisation effect of Nonidet P-40, Triton X-100 and CHAPS in the detection of MHC-like glycoproteins. (Submitted).Google Scholar
  19. Lilly, F.: The inheritance of susceptibility to the Gross leukaemia virus in mice. Genetics, 53: 529, 1966.PubMedGoogle Scholar
  20. Ljunggren, H-G. & Karre, K.: Variations in MHC antigen expression on tumours and its significance. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression: opposing influences of T cell and natural killer mediated resistance. J. Immunogenetics, 13: 141–151, 1986.CrossRefGoogle Scholar
  21. Mann, D., Popovic, M., Sarin, P., Murray, C., Reitz, M.S., Strong, D.M., Haynes, B.F., Gallo, R.C. & Blattner, W.A.: Cell lines producing human T-cell lymphoma virus show altered HLA expression. Nature, 305: 58–59, 1983.PubMedCrossRefGoogle Scholar
  22. Marelli, O., Testorelli, C., Canti, G., Festenstein, H. & Nicolin, A.: Immunological cross-reactivity between H-2DK product and DTIC-treated H-2d lymphoma. J. Immunogenetics, 9: 407–412, 1982.CrossRefGoogle Scholar
  23. Martin, W.J.: Immune surveillance directed against derepressed cellular and viral antigens. Cell. Immunol., 15: 1, 1975.PubMedCrossRefGoogle Scholar
  24. Martin, W.J., Gibson, T.G., Martin, S.W. & Rice, J.M.: Derepressed alloantigen on lung tumour cells transplacentally induced, coded by H-2 liked gene. Science, 194: 532, 1976.PubMedCrossRefGoogle Scholar
  25. Meruello, D.: H-2D control of leukaemia susceptibility: mechanisms and implications. J. Immunogenetics, 7: 81–90, 1980.CrossRefGoogle Scholar
  26. Old, E., Boyse, E.A. & Stockert, E.: The G (Gross) leukaemia antigen. Cancer Res., 25: 813, 1965.PubMedGoogle Scholar
  27. Old, L.J. & Stockert, E.: Immunogenetics of cell surface antigens of mouse leukaemia. Ann. Rev. Genet., 17: 127–160, 1977.CrossRefGoogle Scholar
  28. Parmiani, G.: Foreign histocompatibility determinants as tumour associated transplantation antigens of chemically induced murine fibrosarcoma. In: HLA System — New Aspects (ed. G.B. Ferrara ), Elsevier/North Holland Biomedical Press, p. 45, 1977.Google Scholar
  29. Philipps, G., Stauss, H.J., Wortzel, R.D. & Schreiber, H.: Unusual or aberrant MHC antigen expression on tumours. A novel MHC Class I molecule as a tumour-specific antigen. Correlation between the antibody-defined and the CTL-defined target structure. J. of Immunogenetics, 13: 93–99, 1986.CrossRefGoogle Scholar
  30. Schäfer, A. & Schmidt, W.: Resistance to cellular immune response in AKR leukaemias. Eur. J. Immunol., 16: 753, 1986.PubMedCrossRefGoogle Scholar
  31. Schmidt, W., Leben, L., Atfield, G. & Festenstein, H.: Variation of expression of histocompatibility antigens on tumour cells: absence of H-2Kk gene products from a Gross virus induced leukaemia in BALB.K. Immunogenetics, 14: 323–339, 1981.PubMedCrossRefGoogle Scholar
  32. Schmidt, W., Alonzo, A., Leben, L. & Festenstein, H.: Differential regulation of H-2 antigen expression in tumours and its biological consequences. Transpl. Proc., 13: 1814–1818, 1981.Google Scholar
  33. Schmidt, W. & Festenstein, H.: Resistance to cell-mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukaemia. Immunogenetics, 16: 257–264, 1982.PubMedCrossRefGoogle Scholar
  34. Schmidt, W.: H-2 specific antibodies induced by injection of syngeneic leukaemia cells. Immunogenetics, 25: 215–221, 1987.PubMedCrossRefGoogle Scholar
  35. Schrier, P.I., Bernards, R., Vaessen, R.T.M.J., Houweling, A. & van der Eb, A.J.: Expression of Class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature, 309: 771, 1983.CrossRefGoogle Scholar
  36. Sonoda, S., Yashiki, S., Takahashi, K., Matsumoto, T., Matsumoto, M., Yunoki, K., Sato, K., Inoko, H. & Tsuji, K.: Altered expression of MHC Class I and II antigens in T and B lymphocytes of adult T cell leukaemia-lymphoma patients. Proceedings from the Third Asia-Oceania Histocompatibility Workshop Conference (ed. M. Aizawa), Hokkaido University Press, Sapporo, Japan, p.628–631.Google Scholar
  37. Stauss, H.J., Linsk, R., Fischer, A., Watts, S., Banasiak, D., Haberman, A., Clark, I., Forman, J., McMillan, M., Schreiber, H. & Goodenow, R.S.: The MHC genes encoding the tumour specific Class I antigens expressed on a murine fibrosarcoma. J. Immunogenetics, 13: 101–112, 1986.CrossRefGoogle Scholar
  38. Steinmetz, M., Frelinger, J.S., Fisher, D., Hunkapiller, T., Pereira, D., Weissman, S.M., Uehara, H., Nathenson, S. & Hood, L.: Three cDNA clones encoding mouse transplantation antigens: Homology to Immunoglobulin genes. Cell, 24: 125–134, 1981.PubMedCrossRefGoogle Scholar
  39. Tanaka, K., Hayashi, H., Hamada, C., Khoury, G. & Gilbert, J.: Expression of major histocompatibility complex Class I antigens as a strategy for the potentiation of immune recognition of tumour cells. Proc. Natl. Acad. Sci. (USA), 83: 8723–8727, 1986.CrossRefGoogle Scholar
  40. Wallich, R., Bulbuc, N., Hammerling, G., Katzav, S., Segal, S. & Feldman, M.: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature, 315: 301, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Hilliard Festenstein
    • 1
  • Mario Labeta
    • 1
  1. 1.Department of ImmunologyThe London Hospital Medical CollegeLondonUK

Personalised recommendations